Current Atherosclerosis Reports

Article	Citations
Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients	72
APOA1: a Protein with Multiple Therapeutic Functions	70
Social Determinants of Health and Cardiovascular Disease: Current State and Future Directions Towards Healthcare Equity	63
Food Insecurity and Cardiovascular Disease Risk	62
COVID and Cardiovascular Disease: What We Know in 2021	62
Periodontal Inflammation and the Risk of Cardiovascular Disease	57
CD36 in Atherosclerosis: Pathophysiological Mechanisms and Therapeutic Implications	56
Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis	54
Trimethylamine N-Oxide (TMAO), Diet and Cardiovascular Disease	54
Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?	51
High-Density Lipoproteins and Serum Amyloid A (SAA)	49
Time-Restricted Eating to Improve Cardiovascular Health	43
A Review of the Relationship Between CTRP Family and Coronary Artery Disease	42
Lipid Lowering Drugs: Present Status and Future Developments	40
New Pharmacological Approaches to Target PCSK9	39
The Role of the Gut Microbiota in Coronary Heart Disease	39
The Effect of Statins through Mast Cells in the Pathophysiology of Atherosclerosis: a Review	38
Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions	38
Microparticles (Exosomes) and Atherosclerosis	37
ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets	36
Long-Term Cardiovascular Effects of COVID-19: Emerging Data Relevant to the Cardiovascular Clinician	34
Birth Weight and Risk of Cardiovascular Disease Incidence in Adulthood: a Dose-Response Meta-analysis	33
The Long Non-coding Road to Atherosclerosis	33
Women Living with Familial Hypercholesterolemia: Challenges and Considerations Surrounding Their Care	32
Statins and Inflammation	32

The Association Between Periodontitis and Cardiovascular Disease: an Update	32
Lomitapide–a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia	31
Clinical Pharmacology of Statins: an Update	30
Phytosterols and Cardiovascular Disease	30
Targeting Inflammation to Reduce Residual Cardiovascular Risk	29
More than Just a Monolayer: the Multifaceted Role of Endothelial Cells in the Pathophysiology of Atherosclerosis	29
Exosomes: Multifaceted Messengers in Atherosclerosis	29
Digital Health Innovations to Improve Cardiovascular Disease Care	28
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond	28
Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues	27
HDL-small RNA Export, Transport, and Functional Delivery in Atherosclerosis	27
Association Between Caliber of Retinal Vessels and Cardiovascular Disease: a Systematic Review and Meta-Analysis	26
Nutrition and Gastrointestinal Microbiota, Microbial-Derived Secondary Bile Acids, and Cardiovascular Disease	25
Inflammatory Cytokines and Atherosclerotic Plaque Progression. Therapeutic Implications	25
Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials	25
Psoriasis and Cardiovascular Disease: Novel Mechanisms and Evolving Therapeutics	23
The Knowns and Unknowns of Contemporary Statin Therapy for Familial Hypercholesterolemia	23
Bempedoic Acid: for Whom and When	23
High HDL-Cholesterol Paradox: SCARB1-LAG3-HDL Axis	23
Menopausal Hormone Therapy: a Comprehensive Review	23
Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors	22
GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?	22
Statins in a Distorted Mirror of Media	22
Structural Basis for Vital Function and Malfunction of Serum Amyloid A: an Acute-Phase Protein that Wears Hydrophobicity on Its Sleeve	21
Understanding Immigration as a Social Determinant of Health: Cardiovascular Disease in Hispanics/Latinos and South Asians in the United States	21
Overweight, Obesity, and CVD Risk: a Focus on Visceral/Ectopic Fat	21
Apolipoprotein E and Atherosclerosis	21
The Difference Between High Density Lipoprotein Subfractions and Subspecies: an Evolving Model in Cardiovascular Disease and Diabetes	20
Impact of Different Doses of Omega-3 Fatty Acids on Cardiovascular Outcomes: a Pairwise and Network Meta-analysis	19
Alcohol Consumption and Cardiovascular Disease Risk: Placing New Data in Context	19
Familial Chylomicronemia Syndrome (FCS): Recent Data on Diagnosis and Treatment	19
Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease	19
Current Approach to the Diagnosis and Treatment of Heterozygote and Homozygous FH Children and Adolescents	18
Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis	18
Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease	18
RNA Silencing in the Management of Dyslipidemias	18
Spontaneous Coronary Artery Dissection: Latest Developments and New Frontiers	18
Lipid Phenotypes and DNA Methylation: a Review of the Literature	17
Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?	17
Ambient Air Pollution and Atherosclerosis: Recent Updates	17
Lipoprotein (a): When to Measure and How to Treat?	17
Inclisiran: How Widely and When Should We Use It?	17
The Genetic Basis of Hypertriglyceridemia	17
Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease	17
Dyslipidemia Management in Pregnancy: Why Is It not Covered in the Guidelines?	17
Nutrient Profiling Systems, Front of Pack Labeling, and Consumer Behavior	17
MicroRNAs and Circular RNAs in Lipoprotein Metabolism	16
Wall Shear Stress Alteration: a Local Risk Factor of Atherosclerosis	16
Metabolomic Biomarkers of Healthy Dietary Patterns and Cardiovascular Outcomes	16
The Role of Statins in Current Guidelines	16

Premature Atherosclerotic Cardiovascular Disease: What Have We Learned Recently?	16
LDL Apheresis and Lp (a) Apheresis: A Clinician’s Perspective	16
Obesity Management in Cardiometabolic Disease: State of the Art	15
2019-Novel Coronavirus-Related Acute Cardiac Injury Cannot Be Ignored	15
Rare Treatments for Rare Dyslipidemias: New Perspectives in the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) and Familial Chylomicronemia Syndrome (FCS)	15
Inflammatory Links Between Hypertriglyceridemia and Atherogenesis	15
Lp(a): a New Pathway to Target?	15
Ultra-processed Foods and Cardiometabolic Health Outcomes: from Evidence to Practice	15
Managing Ischemic Heart Disease in Women: Role of a Women’s Heart Center	14
The Role of Sex-Specific Risk Factors in the Risk Assessment of Atherosclerotic Cardiovascular Disease for Primary Prevention in Women	14
The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?	14
Sex Differences in Coronary Atherosclerosis	14
The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia	13
Highlights from Studies in Cardiovascular Disease Prevention Presented at the Digital 2020 European Society of Cardiology Congress: Prevention Is Alive and Well	13
The Role of High-Density Lipoprotein Cholesterol in 2022	13
The Role of Phospholipid Transfer Protein in the Development of Atherosclerosis	13
Genetic Risk Factors of Intracranial Atherosclerosis	13
Novel RNAi-Based Therapies for Atherosclerosis	13
Biology, Bias, or Both? The Contribution of Sex and Gender to the Disparity in Cardiovascular Outcomes Between Women and Men	13
Lipoprotein (a): Recent Updates on a Unique Lipoprotein	12
Hypertension in Women Across the Lifespan	12
Watermelon and l-Citrulline in Cardio-Metabolic Health: Review of the Evidence 2000–2020	12
PCSK9 Inhibition and Risk of Diabetes: Should We Worry?	12
The Impact of Psychological Functioning on Cardiovascular Disease	12
A Nutrigenetic Update on CETP Gene–Diet Interactions on Lipid-Related Outcomes	12
Contributions of Food Environments to Dietary Quality and Cardiovascular Disease Risk	12
Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management	12
Gene-Environment Interactions for Cardiovascular Disease	12
ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis	12
How Do We Incorporate Polygenic Risk Scores in Cardiovascular Disease Risk Assessment and Management?	12
Nutrition Disparities and Cardiovascular Health	12
Dietary Influences on Atherosclerotic Cardiovascular Disease Risk	12
Excessive Supraventricular Ectopic Activity and Adverse Cardiovascular Outcomes: a Systematic Review and Meta-analysis	11
Lipoprotein(a) as Part of the Diagnosis of Clinical Familial Hypercholesterolemia	11
Therapeutic Apheresis for Management of Lp(a) Hyperlipoproteinemia	11
New Classification of Macrophages in Plaques: a Revolution	11
RNA Therapeutics: the Next Generation of Drugs for Cardiovascular Diseases	11
The Dynamic Interplay of Healthy Lifestyle Behaviors for Cardiovascular Health	10
Mechanical Circulatory Support: a Comprehensive Review With a Focus on Women	10
Highlights of Studies in Cardiovascular Disease Prevention Presented at the 2020 American College of Cardiology Annual Scientific Session	10
Degenerative Severe Aortic Stenosis and Concomitant Coronary Artery Disease: What Is Changing in the Era of the “Transcatheter Revolution”?	10
Colchicine and Cardiovascular Outcomes: a Critical Appraisal of Recent Studies	10
Free Cholesterol Bioavailability and Atherosclerosis	10
SR-B1’s Next Top Model: Structural Perspectives on the Functions of the HDL Receptor	10
Novel Functions of Endothelial Scavenger Receptor Class B Type I	10
The Role of Calorie Restriction in the Prevention of Cardiovascular Disease	9
Familial Hypercholesterolemia and Lipoprotein(a): Two Partners in Crime?	9
Is Any Cardiovascular Disease-Specific DNA Methylation Biomarker Within Reach?	9
APOC-III: a Gatekeeper in Controlling Triglyceride Metabolism	9
Omega n-3 Supplementation: Exploring the Cardiovascular Benefits Beyond Lipoprotein Reduction	9
Updates on the Use of Subclinical Atherosclerosis to Predict Risk of Cardiovascular Events in Heterozygous Familial Hypercholesterolemia	9
Dairy Foods: Is Its Cardiovascular Risk Profile Changing?	8
Takotsubo Syndrome: Uncovering Myths and Misconceptions	8
Update on Plant-Based Diets and Cardiometabolic Risk	8
Lipoprotein Apheresis: Current Recommendations for Treating Familial Hypercholesterolemia and Elevated Lipoprotein(a)	8
Gender Differences in Residual Risk Factors for Major Adverse Cardiovascular Events Following ACS and How to Bridge the Gap	8
Management of Structural Heart Disease and Acute Coronary Syndromes in the COVID-19 Pandemic	8
Selective Peroxisome Proliferator–Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?	8
ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future	8
Anemia in Cardiovascular Disease: Marker of Disease Severity or Disease-modifying Therapeutic Target?	8
Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease (MINOCA): a Review of the Present and Preview of the Future	8
Plant- and Animal-Based Protein-Rich Foods and Cardiovascular Health	8
SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?	8
Prevention of Atherosclerotic Cardiovascular Disease in Children with Familial Hypercholesterolemia	8
Biological Factors Linking ApoE ε4 Variant and Severe COVID-19	8
Genetics of Lipoprotein(a): Cardiovascular Disease and Future Therapy	8
State of the Art in Noninvasive Imaging of Ischemic Heart Disease and Coronary Microvascular Dysfunction in Women: Indications, Performance, and Limitations	8
Behavioral Medicine for Sedentary Behavior, Daily Physical Activity, and Exercise to Prevent Cardiovascular Disease: A Review	8
Evolution of Coronary Calcium Screening for Assessment of Atherosclerotic Cardiovascular Disease Risk and Role in Preventive Cardiology	7
Evidence Gaps in Assessments of the Healthiness of Online Supermarkets Highlight the Need for New Monitoring Tools: a Systematic Review	7
Reverse Cholesterol Transport Dysfunction Is a Feature of Familial Hypercholesterolemia	7
LDL-C: The Only Causal Risk Factor for ASCVD. Why Is It Still Overlooked and Underestimated?	7
Controversies in the Use of Omega-3 Fatty Acids to Prevent Atherosclerosis	7
Management of Hypercholesterolemia in Pregnant Women with Atherosclerotic Cardiovascular Disease	7
Clonal Hematopoiesis of Indeterminate Potential: an Expanding Genetic Cause of Cardiovascular Disease	7
Moving the Needle on Atherosclerotic Cardiovascular Disease and Heart Failure with Influenza Vaccination	7
Recent Advances in Stent Technology: Do They Reduce Cardiovascular Events?	7
Sustainable Diets for Cardiovascular Disease Prevention and Management	7
Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention	7
mHealth Technology and CVD Risk Reduction	7

Childhood Obesity and Cardiovascular Disease Risk	7
Beta-blockers for Atherosclerosis Prevention: a Missed Opportunity?	7
A Contemporary Review of Epidemiology, Risk Factors, Etiology, and Outcomes of Premature Stroke	7
The Effect of GLP-1 Receptor Agonists on Postprandial Lipaemia	7
Diet, Food Insecurity, and CVD Risk in Sexual and Gender Minority Adults	7
From ‘Omics to Multi-omics Technologies: the Discovery of Novel Causal Mediators	7
Monogenic Versus Polygenic Forms of Hypercholesterolemia and Cardiovascular Risk: Are There Any Differences?	7
Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome	6
Diabetes, Lipids, and CV Risk	6
Transintestinal cholesterol excretion in health and disease	6
Highlights from Studies Presented at the Virtual American College of Cardiology Scientific Sessions 2021: Staying Updated with the Latest Advancements in Prevention	6
Medical Nutrition Therapy Provided by Dietitians is Effective and Saves Healthcare Costs in the Management of Adults with Dyslipidemia	6
Highlights of Cardiovascular Disease Studies Presented at the 2021 American Heart Association Scientific Sessions	6
Immunogenetics of Atherosclerosis—Link between Lipids, Immunity, and Genes	6
Cardio-Obstetrics: the Next Frontier in Cardiovascular Disease Prevention	6
Coconut Oil and Cardiovascular Disease Risk	6
Nutrition as Treatment Modality in Heart Failure	6
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American Heart Association Scientific Sessions	6
Strengthening the Learning Health System in Cardiovascular Disease Prevention: Time to Leverage Big Data and Digital Solutions	6
Update on Sitosterolemia and Atherosclerosis	6
Differences in the 2020 ESC Versus 2015 ESC and 2014 ACC/AHA Guidelines on the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation	6
Preventive Cardiology and Risk Assessment: Beyond LDL	6
Updates in Drug Treatment of Severe Hypertriglyceridemia	5
PCSK9 Inhibitors in Real-world Practice: Analysis of Data from 314 Patients and 2 Years of Experience in a Center of Preventive Cardiology	5
Imaging Approaches to the Diagnosis of Vascular Diseases	5
PCSK9 Monoclonal Antibodies: New Developments and Their Relevance in a Nucleic Acid–Based Therapy Era	5
Hypertension and Dyslipidemia: the Two Partners in Endothelium-Related Crime	5
Breast Arterial Calcification: A Potential Biomarker for Atherosclerotic Cardiovascular Disease Risk?	5
Even “WISE-R?”—an Update on the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation	5
Improving Maternal Cardiovascular Health in Underserved Populations: a Narrative Review of Behavioral Intervention Trials Targeting Postpartum Weight Retention	5
Telomere Length: Implications for Atherogenesis	5
Highlights from Studies Presented at the American Heart Association Scientific Session 2020: Navigating New Roads in Prevention	5
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American College of Cardiology Scientific Sessions	5
COVID-19 and Cardiometabolic Health: Lessons Gleaned from the Pandemic and Insights for the Next Wave	5